Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -82.81% is 71% above its 5-year average of -288.64%, near the high end of its 5-year range (-1175.53%–-60.24%).
7.67% below its 12-month average of -76.91%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -60.24%.
EBITDA MARGIN
-82.81%
EBITDA MARGIN AVG TTM
-76.91%
EBITDA MARGIN AVG 3Y
-189.63%
EBITDA MARGIN AVG 5Y
-288.64%
EBITDA MARGIN AVG 10Y
-280.74%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-7.67%
CURRENT VS 3Y AVG
+56.33%
CURRENT VS 5Y AVG
+71.31%
CURRENT VS 10Y AVG
+70.50%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Bionano Genomics, Inc.
Market Cap
$16.75M
EBITDA Margin
-82.81%
TTM Avg
-76.91%
3Y Avg
-189.63%
5Y Avg
-288.64%
Market Cap
$16.85M
EBITDA Margin
-579.88%
TTM Avg
-374.35%
3Y Avg
-344.55%
5Y Avg
-411.92%
Market Cap
$17.09M
EBITDA Margin
-168.69%
TTM Avg
-262.41%
3Y Avg
-983.34%
5Y Avg
-3401.51%
Market Cap
$17.15M
EBITDA Margin
-521.61%
TTM Avg
-265.78%
3Y Avg
-984.51%
5Y Avg
-733.51%
Market Cap
$15.91M
EBITDA Margin
-14633.33%
TTM Avg
-7486.14%
3Y Avg
-4543.27%
5Y Avg
-3157.51%
Market Cap
$15.88M
EBITDA Margin
-13679.31%
TTM Avg
-8051.39%
3Y Avg
-4553.85%
5Y Avg
-5076.49%
Market Cap
$15.44M
EBITDA Margin
-468.17%
TTM Avg
-602.06%
3Y Avg
-602.06%
5Y Avg
-23374.02%
Market Cap
$15.04M
EBITDA Margin
-29916.57%
TTM Avg
-29916.57%
3Y Avg
-29916.57%
5Y Avg
-29916.57%
Market Cap
$18.54M
EBITDA Margin
-23.24%
TTM Avg
-24.75%
3Y Avg
-25.93%
5Y Avg
-17.56%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bionano Genomics, Inc. (BNGO) | $16.75M | -82.81% | -76.91% | -189.63% | -288.64% |
| Dyadic International, Inc. (DYAI)vs › | $16.85M | -579.88% | -374.35% | -344.55% | -411.92% |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.09M | -168.69% | -262.41% | -983.34% | -3401.51% |
| Lipocine Inc. (LPCN)vs › | $17.15M | -521.61% | -265.78% | -984.51% | -733.51% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.91M | -14633.33% | -7486.14% | -4543.27% | -3157.51% |
| BioCardia, Inc. (BCDA)vs › | $15.88M | -13679.31% | -8051.39% | -4553.85% | -5076.49% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.44M | -468.17% | -602.06% | -602.06% | -23374.02% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.04M | -29916.57% | -29916.57% | -29916.57% | -29916.57% |
| Cosmos Health Inc. (COSM)vs › | $18.54M | -23.24% | -24.75% | -25.93% | -17.56% |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.70M | -779.07% | -389.93% | -389.93% | -2320.55% |
Gross Margin
21.9%
EBITDA Margin
-82.8%
Operating Margin
-117.0%
Net Margin
-106.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -60.24% |
| 2026-03-31 | -82.79% |
| 2025-12-31 | -77.32% |
| 2025-09-30 | -82.95% |
| 2025-06-30 | -81.26% |
| 2025-03-31 | -92.61% |
| 2024-12-31 | -116.28% |
| 2024-09-30 | -629.36% |
| 2024-06-30 | -179.89% |
| 2024-03-31 | -320.05% |
| 2023-12-31 | -153.33% |
| 2023-09-30 | -1175.53% |
| 2023-06-30 | -399.50% |
| 2023-03-31 | -466.65% |
| 2022-12-31 | -421.98% |
| 2022-09-30 | -411.62% |
| 2022-06-30 | -446.42% |
| 2022-03-31 | -486.38% |
| 2021-12-31 | -417.36% |
| 2021-09-30 | -432.91% |
| 2021-06-30 | -413.90% |
| 2021-03-31 | -338.23% |
| 2020-12-31 | -264.56% |
| 2020-09-30 | -451.23% |
| 2020-06-30 | -604.06% |
| 2020-03-31 | -833.27% |
| 2019-12-31 | -245.51% |
| 2019-09-30 | -163.21% |
| 2019-06-30 | -302.46% |
| 2019-03-31 | -319.26% |
| 2018-12-31 | -148.19% |
| 2018-09-30 | -197.18% |
| 2018-06-30 | -106.94% |
| 2018-03-31 | -223.02% |
| 2017-12-31 | -165.20% |
| 2017-09-30 | -174.65% |
| 2017-06-30 | -290.91% |
| 2017-03-31 | -339.10% |
